Pharma & Bio
Technology
“Aiming to Stabilize Supply Chains”… Tax Credits for Biotech Raw Materials and Supplies; CDMOs to Benefit the Most
The government is pushing forward with a plan to designate key raw materials and components necessary for the production of biopharmaceuticals and vaccines as strategic goods and to provide tax credit…
Technology
Alteogen Inc., Which Aimed for a '30 Trillion Valuation,' Remains on KOSDAQ After 7 Months… Beneficiaries of the Promotion-Demotion System
Alteogen Inc.(196170), the company with the largest market capitalization on KOSDAQ, has tentatively put on hold its plans to relist on the Korea Exchange (KOSPI) and opted to remain on KOSDAQ. This c…
Lifestyle
[Blue Ocean Veterinary Medical Devices] (2) RAYENCE CO., LTD. Subsidiary Woori-En Holds Overwhelming Lead in the Veterinary Electronic Medical Record Market
As medical technology advances, the treatment of human diseases is evolving toward “personalized” and “precision medicine.” Consequently, demand for personalized treatment and precision medicine is no…
Technology
Curiosis Inc.’s “Two-Track” Supply Contract… Is a Turnaround in Earnings Possible?
(Graphic: ChatGPT)
#Curiosis Inc. has secured a German company, M, as a client following global life sciences firm Revvity Biomed, marking its expansion into the Original Design Manufacturing (ODM…
Lifestyle
Chasing High Returns Despite Risks? Three "Problematic" Biotech Stocks Rank Among the Top 15 Gainers [K-Bio Pulse]
As the domestic stock market enters a correction phase, excess liquidity is flowing back into the pharmaceutical and biotech sectors. Investors are even returning to companies previously labeled as “p…
Lifestyle
Is Investor Sentiment Returning? Even the 'Troublesome Trio' Makes the 'Top 15 Stock Gainers' [Bio Spotlight]
As the domestic securities market has recently entered a correction phase, a trend has been observed in which capital, having lost its direction, is once again flowing back into the pharmaceutical and…
Lifestyle
"From Efficacy Failures to Controversy Over Internal Analysis"... Kolon TissueGene's U.S. Phase 3 Trial Objectivity Under Scrutiny
Kolon TissueGene CI (Photo courtesy of Kolon TissueGene)
Kolon TissueGene’s TG-C, a cell-gene therapy for osteoarthritis, failed to demonstrate efficacy in the first topline results from its U.S. …
Technology
'KOLON CORPORATION's Fourth Child' TG-C Fails U.S. Phase 3 Trial… 27-Year Quest for a New Drug 'Shaken'
#KOLON CORPORATION’s “TG-C,” a cell- and gene-based therapy for osteoarthritis that the company has been developing for 27 years, has failed its U.S. Phase 3 clinical trial. TG-C is a new drug to whic…
Lifestyle
Celltrion and Samsung, Not SMEs, Benefit from Biosimilar Phase 3 Exemption... Why?
With the official announcement of the Phase 3 clinical trial exemption for biosimilars, biosimilar companies are busy crunching the numbers. On the 14th, South Korea’s Ministry of Food and Drug Safety…
Technology
Kim Mi-hyung, CEO of ANTEROGEN CO., LTD.: “Over 1,000 Potential Patients for Alostemcit in Japan”
Ahead of the inclusion of “Alostemcit,” a treatment for epidermolysis bullosa, in Japan’s national health insurance reimbursement list, ANTEROGEN CO., LTD.(065660)has estimated the number of potential…